This, in combination with a correlation of intracranial response to extracranial response in 86% of cases for those with BM initially left untreated, suggests that ICI in combination with close MR-C control might be a potential initial treatment strategy in a subgroup of NSCLC patients with BM, in particular, for those with smaller size BM, a PD-L1 (TPS) status ≥50%, ICI given in first line and for those without neurological symptoms. The gene discussed is CD274; the disease is non-small cell lung carcinoma.